By
WilD on
November 26, 2011
Welcome back to our Saturday diabetes advice column, Ask D’Mine, hosted by veteran type 1, diabetes author and community educator Wil Dubois — where myths get busted and unseemly topics sometimes see the light of day. Hey, where else ya gonna turn?
{Need help navigating life with diabetes? Email us at AskDMine@diabetesmine.com}
First things first this week:
Exercising over 250 mg/dL CORRECTION:
Last week we talked about how it’s generally considered unsafe to start…
Read more »
Health professionals reportedly are receiving letters this week alerting them to an FDA warning just issued about risks of thyroid cancer and pancreatitis associated with the popular type 2 diabetes drug liraglutide (Victoza). Yikes!
According to MSM reports, the evidence was found in mice, and it’s unclear if the serious risks translate to humans — but there was enough concern to issue the follow warning:
“Clinical trials have shown more cases of pancreatitis with liraglutide…
Read more »
The world of type 2 diabetes drugs is wacky indeed. While Amylin’s long-acting version of Byetta — called Bydureon and predicted by many experts to become a blockbuster — is still held up at FDA, the agency approved a new oral drug earlier this month that is reportedly unremarkable except in the lawsuit it has spurred.
The drug is called linagliptin, brand name Tradjenta, a new oral DPP-4 inhibitor from Eli Lilly and Boehringer that…
Read more »
Last week, the New York Chapter of the Juvenile Diabetes Research Foundation hosted their annual research briefing. Many chapters around the country host similar research briefings, and I was excited to find out that our local meeting would feature Dr. Sanjoy Dutta, Director of Glucose Control Therapies within the Treatment Therapies Program.
I want to note that although there’s been a lot of controversy surrounding the addition of treatment goals to JDRF’s mission, I whole-heatedly…
Read more »
